Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and JULIE MAK

AstraZeneca Stock Scores RS Rating Upgrade

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. AstraZeneca ADR stock now clears that threshold, with a jump from 80 to 83 Friday.

This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest climbs.

Risk Management In The Stock Market: How Much Money To Invest Now

Is AstraZeneca Stock A Buy?

The IBD 50 stock is trying to complete a cup without handle with an 87.67 buy point. This is not the time to buy stocks during a market correction, but build a watchlist of possible emerging leaders once the market trend turns around.

 

In terms of revenue and profits, AstraZeneca has posted rising EPS growth over the last two quarters. Sales gains have also risen over the same time frame.

AstraZeneca stock earns the No. 1 rank among its peers in the Medical-Diversified industry group. Abbott Laboratories and Eli Lilly are also among the group's highest-rated stocks.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.